Bicycle Therapeutics Ltd (BCYC) is a pioneering clinical-stage biopharmaceutical company based in Cambridge, UK, focused on developing breakthrough therapeutics through its proprietary bicyclic peptide technology. The firm addresses critical unmet medical needs, with a concentrated emphasis on oncology, aiming to transform treatment paradigms with its innovative drug design approach. With a strong pipeline of therapeutic candidates undergoing clinical trials, Bicycle is poised to significantly impact patient care and redefine industry standards in the biopharmaceutical sector.